- Home
- INTS vs PYN Comparison
INTS vs PYN Comparison
Compare INTS & PYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- PYN
- Stock Information
- Founded
- INTS 2012
- PYN 2002
- Country
- INTS United States
- PYN United States
- Employees
- INTS N/A
- PYN N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- PYN Investment Managers
- Sector
- INTS Health Care
- PYN Finance
- Exchange
- INTS Nasdaq
- PYN Nasdaq
- Market Cap
- INTS 7.4M
- PYN 30.1M
- IPO Year
- INTS 2023
- PYN N/A
- Fundamental
- Price
- INTS $0.33
- PYN $5.29
- Analyst Decision
- INTS Strong Buy
- PYN
- Analyst Count
- INTS 3
- PYN 0
- Target Price
- INTS $8.50
- PYN N/A
- AVG Volume (30 Days)
- INTS 3.7M
- PYN 19.9K
- Earning Date
- INTS 08-07-2025
- PYN 01-01-0001
- Dividend Yield
- INTS N/A
- PYN 5.07%
- EPS Growth
- INTS N/A
- PYN N/A
- EPS
- INTS N/A
- PYN N/A
- Revenue
- INTS N/A
- PYN N/A
- Revenue This Year
- INTS N/A
- PYN N/A
- Revenue Next Year
- INTS N/A
- PYN N/A
- P/E Ratio
- INTS N/A
- PYN N/A
- Revenue Growth
- INTS N/A
- PYN N/A
- 52 Week Low
- INTS $0.26
- PYN $4.84
- 52 Week High
- INTS $5.10
- PYN $6.60
- Technical
- Relative Strength Index (RSI)
- INTS 41.29
- PYN 49.80
- Support Level
- INTS $0.26
- PYN $5.25
- Resistance Level
- INTS $0.32
- PYN $5.37
- Average True Range (ATR)
- INTS 0.03
- PYN 0.10
- MACD
- INTS 0.02
- PYN 0.01
- Stochastic Oscillator
- INTS 62.56
- PYN 9.59
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.